Y-mAbs acquired by Perseus BidCo US; tender offer completed at $8.60/share, ~$413M total

Y-mAbs Therapeutics, Inc.

Approximately 39.8M shares (~87.22%) tendered; Purchaser accepted all validly tendered shares.
Merger closed Sep 16; each outstanding share (except excluded) converted to $8.60 cash.
Aggregate consideration ~$413M funded via cash on hand and short-term financing.
Shares to be delisted from Nasdaq; company will file Form 15 to suspend reporting obligations.
All prior directors and officers resigned; new board and officers appointed (Vanessa Wolfeler, Robert Duffield, Daniel Dolan).

item 2.01 item 3.01 item 3.03 item 5.01 item 5.02 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Y-mAbs Therapeutics, Inc.: By-laws amended and restated in their entirety.

Change: bylaw amendment

Exact text from the filing

at the Effective Time, the Company’s by-laws (the “ By-Laws ”) were amended and restated in their entirety.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Y-mAbs Therapeutics, Inc.: Certificate of incorporation amended and restated in its entirety.

Change: charter amendment

Exact text from the filing

at the Effective Time, the certificate of incorporation of the Company (the “ Certificate of Incorporation ”) was amended and restated in its entirety.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001104659-25-090232

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.